🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMO2024 I ABS1147MO 📊 Phase II RamuNET trial: 71.1% disease control rate in advanced pNET patients treated with dacarbazine + ramucirumab. Of 45 patients, 15.6% had partial responses and 2.2% had a complete response. Most AEs were manageable, with 12.6% grade 3/4. #MedEd

🔥 #ESMO2024 I ABS1141O CABINET Trial/Alliance A021602 update: Cabozantinib (CABO) outperforms placebo in advanced #NETs! Median PFS was 12.7 months for CABO vs. 8.6 months for placebo (HR=0.55, p<0.001). ORR was 22.7% with CABO vs. 10.3% with placebo (p=0.03). #MedEd

❓How can we improve #NET consultations? Tune in as Prof Mohid Khan MD PhD🏴󠁧󠁢󠁷󠁬󠁳󠁿🇬🇧 & Sally Jenkins provide insights on shared decision-making, patient preferences for treatment to enhance #NET management in Ep. 1 of our brand-new podcast series! 🎙️ow.ly/BT9z50TpVaS #MedEd

#SBNETs are on the rise, now the leading subtype in the USA! 🧬 With early-stage diagnosis, smaller tumors, and a 79% lower mortality risk vs SBA, survival rates are significantly higher. Histology is key to better outcomes. Read more: ow.ly/GZmp50Tu3xt #MedEd

🔥It's out now! 📢 Check out our new 2-part podcast series on #NETs! In Ep. 1, Prof Mohid Khan MD PhD🏴󠁧󠁢󠁷󠁬󠁳󠁿🇬🇧 & patient advocate Sally Jenkins discuss shared decision-making. Ep. 2 explores how to individualise treatment decisions for better patient outcomes. ow.ly/h8jU50ToEUK #MedEd

🎙️ New Podcast! 🚨 Shared decision-making & individualised care—what are your goals? Hear from a patient and healthcare professional on optimising communication & personalising #NET treatment. Tune in now! ow.ly/gBKN50Txjhk #MedEd

🔥 New guidelines! Managing rare endocrine tumours such as #neuroendocrine neoplasms & parathyroid carcinoma, from diagnosis to follow-up. Expert insights from global experts including NET CONNECT Member Angela Lamarca! x.com/myESMO/status/… #MedEd

📢🔥Dive into the latest Springer Nature edition on #NETs, covering pathology, molecular biology, diagnostics, and treatment options. Authored by leading experts, it's a valuable resource for oncologists, endocrinologists, and HCPs. ow.ly/T96o50TFyqr #MedEd

❓Did you know that #NETs can be associated with genetic syndromes? 🧬Conditions such as MEN types 1 & 2, von Hippel-Lindau disease, and neurofibromatosis type 1 increase the risk of NETs. 👇Check out the latest factsheets from NET Cancer Day! x.com/netcancerday/s… #MedEd

🎙️If you missed it, now's the time to tune in! Watch Prof Mohid Khan MD PhD🏴󠁧󠁢󠁷󠁬󠁳󠁿🇬🇧 & patient advocate Sally Jenkins discuss the importance of shared decision-making in #NETs, including patient preference for at-home treatment. ow.ly/4xE550TFyUa #MedEd

A recent workshop on #GEP-NENs reviewed 131 studies yielded 24 evidence-based recommendations, including strong guidance for treating symptomatic carcinoid syndrome. 💡How can these insights shape personalised care for patients? x.com/JAMAOnc/status… #MedEd

🎥Join experts Prof. Bergsland & Prof. @louis_demestier in our CME-accredited microlearning on #NETs! Aspects covered include tumour-, patient- and treatment-related factors. ow.ly/6Iyl50TNi0Q #MedEd

New practice guideline alert!📢 #Si-NET cases are rising, often found late. This new guidance paper from NET CONNECT Expert Angela Lamarca covers key points on diagnosis, staging, and treatment in specialised centres. Read more: ow.ly/wYvj50TN9Iz #MedEd

Update on #GEP-NEN biomarkers! 📝 131 studies, 24 key recommendations, and expert insights on imaging, biomarkers, and treatment of midgut NETs with carcinoid syndrome. Dive right into it in JAMA Oncology: ow.ly/4HnM50TNa5z #MedEd

🎓 Don't miss this learning opportunity: bite-sized modules under 5 minutes each & a 30-minute CME assessment on advanced #NET. 🔺 rising incidence of GEP-NETs 🔺management challenges 🔺 treatment strategies that prioritize QoL & toxicity. ow.ly/fNQp50TUtM7 #MedEd

🎙️ Have you listened to our latest podcast yet? We dive into the important topics of shared decision-making and personalised care. Join experts as they discuss how to improve communication and tailor #NET treatment to fit individual needs. ow.ly/2OWG50TU3CQ #MedEd

The COR2ED YouTube account has surpassed 3k subscribers! 🎉 Go and check it out 👇 #MedEd

🔔FREE NEN education for GPs: All you need to know to detect neuroendocrine cancer in general practice only in 60 minutes. CME-accredited, in 6 languages. 🎯Enroll now to #ThinkNENs: incalliance.org/think-nens/ #LetsTalkAboutNETs #MedTwitter #EndoTwitter #generalpractitioners #MedEd

📺 Explore our free #MedED resource developed by Prof. Emily Bergsland and Prof. Louis de Mestier. With practical tools for optimising advanced #NETs treatment and management, focusing on key tumour, patient, and treatment factors. Discover it today! cor2ed.com/net-connect/pr…

Did you catch our recent podcast series? In Ep.1, Dr Mohid Khan & patient advocate Sally Jenkins discuss shared decision-making, and in Ep. 2 they explore how to individualise treatment decisions for better patient outcomes. #LetsTalkAboutNETs Take a look at the highlights📹